Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
Article in Cost Effectiveness and Resource Allocation (February 2024)
The most recent citing publications are shown below. View all 34 publications that cite this research output on Dimensions.
Article in Cost Effectiveness and Resource Allocation (February 2024)
Article in Hematology/Oncology Clinics of North America (January 2024)
Article in Current Oncology (November 2023)